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Abstract 
Purpose Pancreatic neuroendocrine tumours (pNETs) are rare neoplasms, in that they may only 
present symptoms of the hormone secreted, without any generic cancer issues.  It is thus important 
to measure quality of life (QoL) in these patients by evaluating issues relevant and important to 
them, as opposed to general cancer issues. This paper systematically reviews papers addressing the 
symptoms and QoL implications of pNETs, and evaluates each subtype separately, with the aim to 
create a list of QoL issues relevant to these patient groups.  
Methods Medline, EMBASE, CINAHL, PsycInfo, Web of Science, Scopus, OpenGrey and the Cochrane 
Library were searched for publications (1990-2016) reporting symptoms and QoL issues in pNETs.  
Results Following screening of 2797 papers, 69 articles were eligible for data extraction. From these 
papers, 84 different symptoms or QoL issues were extracted:  21 for gastrinoma, 18 for 
glucagonoma, 50 for insulinoma, 10 for VIPoma and 15 for non-functioning pNETs. No issues were 
reported for somatostatinoma, PPoma or ACTHoma. The most frequently reported symptoms vary 
by subtype.  
Conclusions This review emphasises the need to develop a QoL measure for pNETs with specific 
items relevant to the different subtypes, due to the distinct symptoms reported. Following from this 
review, patient and healthcare professional interviews will be conducted in large cohorts across 
many different countries to collect more data on QoL issues specific to pNETs. This data will all be 
collated with the aim to create a QoL measure for pNETs.  
 
Introduction 
Neuroendocrine tumours (NETs) are a heterogeneous group of highly vascular, rare neoplasms that 
arise from cells of the endocrine and nervous system. NETs account for only 0.5% of all malignancies 
with an incidence of between 3-5 per 100,000 population per year but with a high prevalence of 35 
per 100,000 population because of slow tumour growth [1]. NETs arising in the gastrointestinal tract 
are the most common, accounting for two thirds of all NETs [2].  Pancreatic NETs (pNET) specifically, 
have an incidence of ≤1 case per 100,000 population per year and account for 1 to 2 per cent of all 
pancreatic tumours [3-5]. 
The clinical presentation of a pNET is dependent on its functionality. pNETs can be classified as 
functioning (causing hormonal symptoms) or non-functioning [1]. Functioning pNETs secrete a 
predominant hormone and therefore clinically present with a distinct hormonal syndrome. The main 
types of functioning pNETs are insulinoma, gastrinoma, glucagonoma and VIPoma, with others such 
as PPoma, somatostatinoma and ACTH secretion being more rare [6], as demonstrated in Table 1. In 
contrast, non-functioning pNETs do not present clinically with a hormonal syndrome, but often 
present with symptoms of local compression or metastatic disease [7-9]. As a result of these 
symptoms in both functioning and non-functioning tumours, one would expect a pNET to 
significantly impact a patient’s QoL. Further to this, surveillance studies have shown that survival 
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times are generally better in pNETs than many other malignancies, thus patients live with the 
disease for longer [10-12], making QoL a crucial measure when considering the care for these 
patients. Despite this however, little data has been reported on the QoL implications for these 
patients.  
Table 1. 
 Incidence of subtypes of pNETs [13] 
Tumour Incidence per million per year 
Insulinoma 1-2 
Gastrinoma* 1-2 
Glucagonoma 0.1 
VIPoma 0.1 
Somatostatinoma <0.1 
ACTH secreting  <0.1 
Non-syndromic (inc 
Pancreatic Polypeptide) 
1-2 
*About half of cases arise in the duodenum. 
 
Quality of life (QoL) encompasses a multitude of facets including physical health, psychological state, 
social relationships and personal beliefs [14]. Thus, many aspects of a disease affect QoL so it is 
important to assess in patients living with disease, especially for prolonged periods. The EORTC QLQ-
GINET21 Module, designed to be used with QLQ-C30 questionnaire, to assess QoL in patients with 
gastrointestinal NETs was fully validated and published in 2013 on behalf of the EORTC Quality of 
Life Group [15]. Originally this research aimed to encompass QoL implications for NETs of gut and of 
pancreatic origin. However, due to the significant prognostic differences between NETs of gut and of 
pancreatic origin, there is consensus from patients and NET specialists that the QLQ-GINET21 is not 
comprehensive enough for patients with pNETs, and this module should be re-developed for this 
specific patient group. Furthermore, as there is a lack of extensive data available on QoL with pNET 
patients, it is likely that the issues they face have altered due to changes in disease presentation, 
symptoms and therapeutic advances in ten years following the QLQ-GINET21 module development 
[16]. Additionally, not enough patients with functioning pNETs were recruited during the phase 3 
module development of the QLQ-GINET21 and therefore these patients (with the exception of 
gastrinoma) were excluded from the phase 4 validation study, meaning the QLQ-GINET21 is not 
validated for these patients, and further research needs to investigate the QoL issues specific to 
pNET patients. 
The current review aims to identify the QoL issues faced by patients with pNETs by reviewing the 
published literature.  
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Method 
Search strategy and eligibility criteria 
Medline, Embase, CINAHL, PsycInfo, Web of Science, Scopus, OpenGrey and the Cochrane Library 
were searched for publications reporting QoL issues in pNET patients. The search extended from 
January 1990 to May 2016. Terms for pancreatic cancer, pNET and QoL were searched, combined 
using Boolean logic rules. Pancreatic cancer was combined with the free-text term “endocrine” to 
help limit the results to pancreatic cancer of the endocrine system. The GINET21 and other relevant 
existing questionnaires were also searched, combined with the pancreatic cancer and pNET terms.  
To aid the search for literature on QoL in more rare pNETs (i.e. insulinomas, gastrinomas and 
glucogonomas), known symptoms such as hypoglycaemia, duodenal ulceration and necrolytic 
migratory erythema were searched combined with QoL terms. See Table 2 for all search terms 
applied.  
Primary or secondary publications documenting symptoms or QoL issues in patients with pNET were 
included, only excluding conference abstracts, book chapters, literature reviews, case reports (with 
less than 3 cases reported) and animal/basic science studies. In the initial search phase, no language 
restrictions were implemented.  
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Table 2.              
Search terms applied 
Concept (combined by AND) Terms (combined by OR) 
Pancreatic Cancer Pancreatic Neoplasms (MeSH term) 
 
Pancreatic Ductal Carcinoma (MeSH term) 
 
Pancreas Cancer (Emtree term)  
 
Pancrea* Cancer 
 
Pancrea* Carcinoma  
 
Pancrea* Tumo?r 
 
Metastatic Pancrea* Cancer 
 
Pancreatic Neuroendocrine Tumo?r 
Pancreatic Neuroendocrine  pNET  
Tumours Pancrea* NET 
 
Pancreas Islet Cell Tumor (Emtree term) 
 
Islet Cell Adenoma (MeSH term) 
 
Islet Cell Carcinoma (MeSH term) 
 
Endocrine tumo?r pancreas 
 
Endocrine pancrea* tumo?r  
 
Gastro-enteropancreatic neuroendocrine tumo?r  
 
GEPNET 
 
Functioning pancrea* endocrine tumo?r 
 
Non-Functioning pancrea* endocrine tumo?r 
 
Metastatic NET 
 
Gastrinoma (MeSH term) 
 
Insulinoma (MeSH term) 
 
Glucagonoma (MeSH term) 
 
VIPoma (MeSH term) 
 
Werner-Morrison syndrome 
 
Zollinger-Ellison syndrome 
 
Hypoglycemia (Emtree term, MeSH term) 
Hypoglycaemia  Hypoglyc*emia 
Duodenal ulceration Duodenum ulcer (Emtree term) 
 
Duoden* ulcer* 
Necrolytic migratory erythema Necrolytic migratory erythema 
Health-related quality of life Quality of Life (MeSH term) 
 
QoL 
 
Health related quality of life 
 
HRQOL 
 
Subjective health status 
 
Patient reported outcome 
 
Patient based outcome 
 
Patient reported outcome measure 
 
PROM  
 
Self report 
 
Side effect 
 
Impairment 
 
Complaint 
 
Symptom 
Existing questionnaires* GINET21  
 
QLQ C30  
 
PAN26 
 
LMC21 
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HCC18 
 
BIL21 
 
FACT-HEP   
  Norfolk QoL-NET 
* [17-24]  
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Results 
Literature search 
The searches generated 4723 “hits” in total (Fig. 1). This reduced to 2328 after removing duplicates 
(n=1926) and case reports (n=469). Titles and abstracts were screened against the eligibility criteria 
by three of the papers authors (MT, JR and AD). Each reference was coded as ‘accept’ or the reason 
for exclusion. A first round of screening identified 480 papers for inclusion (agreement= 82.1%). 
Discussion between the three raters led to the criteria for inclusion being revised. After which a 
second round of title and abstract screening was conducted. This resulted in 228 papers being 
identified for inclusion (agreement = 91.1%). Papers selected by any of the three reviewers were 
included for full paper review (n=228).  
Full paper screening resulted in a further 159 papers being excluded, including 31 conference 
abstracts, 1 editorial, 21 review articles, 9 case reports, 15 with no mention of QoL or symptoms, 29 
on the wrong patient group, 14 did not specify the type of pNET the patients had and 10 only 
referred to post-treatment issues.  The 29 foreign language articles found were rejected since 
facilities were not available for full translation of all these papers. Thus, 69 papers [25-93] were 
eligible for data extraction, of which most were retrospective in nature but there were also some 
prospective observational studies and quasi-experimental trials.   
 
 
Fig. 1. 
Flow chart of the paper selection process  
 
Issues Generation 
A total of 69 papers were coded for QoL issues/symptoms. All coding for issues was carried out by 
the lead author (MT) using NVivo™ Software [94]. Coding included: the type of pNET the patients 
had, the symptom or quality of life issue reported, and the percentage of patients reporting that 
symptom in each paper (<20%; 20-50%; 50-80%; >80%). All symptoms or quality of life issues 
reported in the papers were coded. 
A total of 141 potential pNET QoL issues were extracted from the literature. Duplicates, test results 
and medical terms (as opposed to symptoms) were removed from the list following review by MT 
and JR, and the list was reduced to 84 issues. There were 21 issues reported for gastrinoma, 18 for 
glucagonoma, 50 for insulinoma, 10 for VIPoma and 15 for non-functioning pNETs. No issues were 
reported for somatostatinoma, PPoma or ACTHoma. All reported issues are displayed in Table 3, 
listed by frequency with most frequently reported at the top of the list. Only two issues were 
common for all subtypes: weight loss and abdominal pain. Weight loss was reported in 21 papers, 
and abdominal pain was reported in 29 papers. 
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The five most frequently reported QoL issues for each of the subtypes are shown in Table 4. This 
data demonstrates the variation in symptoms between subtypes. The numbers reported in table 4 
are the number of papers in which the symptoms are reported for each subtype of pNET and (right 
hand column)  the number of papers in which the symptoms were reported by more than 50% of 
patients. The symptoms were all reported by patients in some way, but since most papers are 
retrospective analyses, the mode of patient reporting is not standardised.   
Of interest is that in gastrinoma the most prominent symptom is of diarrhea, whereas standard 
teaching would suggest that dyspepsia and symptoms from ulcers are most common [95]. Similarly 
diarrhea as a symptom of glucagonoma is not commonly mentioned, but is reported in the most 
number of papers in this study. However, it is not mentioned by more than 50% of the patients in 
any one study with weight loss, abdominal pain and rash being reported more commonly. The 
symptoms of insulinoma as above are similar to what would be expected from standard teaching 
[95]. The top 3 symptoms of VIPoma are well known but flushing is not usually thought to be a 
prominent symptom [95]. The abdominal pain of non-functioning pNET may be expected [96] and 
although jaundice, vomiting anorexia and back pain were reported in some papers, only abdominal 
pain was reported by more than 50% of patients. 
There were no specific symptoms reported for PPoma, confirming the belief that there are often no 
symptoms caused by these tumours [95].  For somatostatinomas, a number of symptoms are quoted 
by clinicians in the literature [95], but there are no papers giving reports of these directly from 
patients. ACTH secreting tumours are very rare and there are again no directly reported symptoms 
but these are well described since they are essentially the same as for (pituitary) Cushings syndrome. 
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Table 3.         
Symptoms/Quality of Life Issues (listed from most frequently reported to least) 
GASTRINOMA GLUCAGONOMA INSULINOMA VIPOMA NF PNET 
Diarrhea 
Abdominal pain 
Heartburn 
Nausea 
Vomiting 
Duodenal ulceration 
GI bleeding 
Peptic ulceration 
Weight loss 
Dyspepsia 
Hematemesis 
Painful swallowing 
Tarry stools 
Appetite change 
Constipation 
Dysphagia 
Epigastralgia 
Jaundice 
Limb edema 
Regurgitation 
Weakness 
Diarrhea 
Weight loss 
Abdominal pain 
NME* 
Nausea 
Cheilitis 
IOM* 
Jaundice 
Peptic ulceration 
Rash 
Vomiting 
Anorexia 
Conjunctivitis 
GERD* 
Glossitis 
Malaise 
Pruritus 
Reduction in taste 
Hypoglycaemia 
Confusion 
Sweating 
Weight gain 
Syncope 
Hunger 
Palpitations 
Seizures 
Abnormal behaviour 
Dizziness 
Tremors 
Coma 
Weakness 
Convulsions 
Headaches 
Drowsiness 
Amnesia 
Paresthesias 
Personality change 
Visual disturbance 
Abdominal pain 
Anxiety 
Blurred vision 
Fainting 
Weight loss 
Diplopia 
Irritability 
Light-headedness 
Nausea 
Pallor 
Speech disturbances 
Vertigo 
Aggressiveness 
Altered mental states 
Awake to eat at night 
Cognitive dysfunction 
CD* 
Fatigue 
Giddiness 
Hallucinations 
Hysteria 
Lack of coordination 
Lethargy 
Memory disorder 
Nocturia 
NAB* 
Peptic ulceration 
Shortness of breath 
Slow reactions 
UAM* 
Weight loss 
Diarrhea 
Dehydration 
Flushing 
Abdominal pain 
Backache 
Coma 
Skin rash 
Vomiting 
Weakness 
Abdominal pain 
Jaundice 
Anorexia 
Vomiting 
Back pain 
Diarrhea 
Dyspepsia 
Fatigue 
Weakness 
Weight loss 
Acute pancreatitis 
Bowel habit change 
Lethargy 
Nausea 
Pruritus 
 
* NME = necrolytic migratory erythema, IOM = inflammation of oral mucosa, CD = 
concentration disturbances, NAB = nocturnal abnormal behaviour, UAM = unable to awaken in 
morning, GERD = gastroesophageal reflux disease 
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Table 4.         
Five most frequently reported symptoms by pNET subtype  
SYMPTOM No. OF PAPERS REPORTING ISSUE No. OF PAPERS WHERE ISSUE REPORTED BY > 50% PATIENTS 
GASTRINOMA 
Diarrhea 16 Crona, J. et al. 2016 [40]; Morocutti, A. et al. 2006 [71]; Matthews, B. D. et al. 2002 
[68]; Waxman, I. et al. 1991 [89]; Wilcox, C. M. et al. 2011 [93]; Hirschowitz, B. I. et 
al. 1996 [58]; Larkin, C. J. et al. 1998 [66]; Wermers, R. A., Fatourechi, V. & Kvols, L. 
K. 1996 [90]; Roy, P. K. et al. 2000 [79]; Roy, P. K. . et al. 2001 [78]; Collen, M. J. et 
al. 1994 [37]; Grozinsky-Glasberg, S. et al. 2011 [54]; Hoffmann, K. M. et al. 2006 
[60]; Smallfield, B. et al. 2010 [80]; Benya, R. V. et al. 1994 [27]; Eriksson, B. et al. 
1990 [47] 
8 Wermers, R. A., Fatourechi, V. & Kvols, L. K. 1996 [90]; Roy, P. K. et al. 
2000 [79]; Roy, P. K. . et al. 2001 [78]; Collen, M. J. et al. 1994 [38]; 
Grozinsky-Glasberg, S. et al. 2011 [54]; Hoffmann, K. M. et al. 2006 
[60]; Smallfield, B. et al. 2010 [80]; Benya, R. V. et al. 1994 [27] 
Abdominal pain 9 Morocutti, A. et al. 2006 [71]; Larkin, C. J. et al. 1998 [66]; Wilcox, C. M. et al. 2011 
[93]; Wermers, R. A., Fatourechi, V. & Kvols, L. K. 1996 [90]; Smallfield, B. et al. 2010 
[80]; Roy, P. K. et al. 2000 [79]; Roy, P. K. et al. 2001 [78]; Hoffmann, K. M. et al. 
2006 [60]; Collen, M. J. et al. 1994 [37] 
5 Smallfield, B. et al. 2010 [80]; Roy, P. K. et al. 2000 [79]; Roy, P. K. . et 
al. 2001 [78]; Hoffmann, K. M. et al. 2006 [60]; Collen, M. J. et al. 1994 
[37] 
Heartburn 9 Morocutti, A. et al. 2006 [71]; Wilcox, C. M. et al. 2011 [93]; Roy, P. K. . et al. 2001 
[78]; Roy, P. K. et al. 2000 [79]; Waxman, I. et al. 1991 [89]; Collen, M. J. et al. 1994 
[37]; Benya, R. V. et al. 1994 [27]; Hoffmann, K. M. et al. 2006 [60]; Smallfield, B. et 
al. 2010 [80] 
4 Collen, M. J. et al. 1994 [37]; Benya, R. V. et al. 1994 [27]; Hoffmann, 
K. M. et al. 2006 [60]; Smallfield, B. et al. 2010 [80] 
Nausea 9 Collen, M. J. et al. 1994 [37]; Waxman, I. et al. 1991 [89]; Morocutti, A. et al. 2006 
[71];  Wermers, R. A., Fatourechi, V. & Kvols, L. K. 1996 [90]; Benya, R. V. et al. 1994 
[27]; Roy, P. K. . et al. 2001 [78]; Roy, P. K. et al. 2000 [79]; Wilcox, C. M. et al. 2011 
[93]; Hoffmann, K. M. et al. 2006 [60] 
1 Hoffmann, K. M. et al. 2006 [60] 
Vomiting 9 Waxman, I. et al. 1991 [89]; Collen, M. J. et al. 1994 [37]; Crona, J. et al. 2016 [40]; 
Wilcox, C. M. et al. 2011 [93]; Roy, P. K. et al. 2001 [78]; Benya, R. V. et al. 1994 [27]; 
Roy, P. K. et al. 2000 [79]; Smallfield, B. et al. 2010 [80]; Wermers, R. A., Fatourechi, 
V. & Kvols, L. K. 1996 [90] 
0  
GLUCAGONOMA 
Weight loss 6   Matthews, B. D. et al. 2002 [68]; Crona, J. et al. 2016 [40]; Chu, Q. D. et al. 2001 
[35]; Wermers, R. A. et al. 1996 [91]; Wermers, R. A., Fatourechi, V. & Kvols, L. K. 
1996 [90]; Eldor, R. et al. 2011 [45] 
4 Chu, Q. D. et al. 2001 [35]; Wermers, R. A. et al. 1996 [91]; Wermers, 
R. A., Fatourechi, V. & Kvols, L. K. 1996 [90]; Eldor, R. et al. 2011 [45] 
Diarrhea 6   Tomassetti, P. et al. 2000 [86]; Wermers, R. A., Fatourechi, V. & Kvols, L. K. 1996 
[90]; Wermers, R. A. et al. 1996 [91]; Chu, Q. D. et al. 2001 [35]; Eldor, R. et al. 2011 
[45]; Tomassetti, P. et al. 1998 [87] 
0  
Abdominal pain 5  Eldor, R. et al. 2011 [45]; Wermers, R. A. et al. 1996 [91]; Wermers, R. A., 
Fatourechi, V. & Kvols, L. K. 1996 [90]; Matthews, B. D. et al. 2002 [68]; Chu, Q. D. et 
al. 2001 [35] 
2 Matthews, B. D. et al. 2002 [68]; Chu, Q. D. et al. 2001 [35] 
Necrolytic 
migratory 
erythema 
4  Tomassetti, P. et al. 2000 [86]; Chu, Q. D. et al. 2001 [35]; Echenique-Elizondo, M. et 
al. 2004 [44]; Eldor, R. et al. 2011 [45] 
2 Echenique-Elizondo, M. et al. 2004 [44]; Eldor, R. et al. 2011 [45] 
Nausea 3  Wermers, R. A., Fatourechi, V. & Kvols, L. K. 1996 [90]; Wermers, R. A. et al. 1996 
[91]; Chu, Q. D. et al. 2001 [35] 
0  
This is the peer-reviewed but unedited manuscript version of the following article: Topping, M., Gray, D., Friend, E., Davies, A., & Ramage, J. (2017). A 
Systematic Review of Symptoms and Quality of Life Issues in Pancreatic Neuroendocrine Tumours, Neuroendocrinology (DOI: 10.1159/000475793).  The 
final, published version is available at https://doi.org/10.1159/000475793  
© 2017 Karger Publishers 
 
INSULINOMA 
Hypoglycaemia 25 Wermers, R. A., Fatourechi, V. & Kvols, L. K. 1996 [90]; Gillams, A. et al. 2005 [52]; 
Van Den Akker, M. et al. 2012 [88]; Toaiari, M. et al. 2013 [85]; Placzkowski, A. et al. 
2009 [77]; Mitrakou, A. et al. 1993 [70]; Gopal, R. A. et al. 2010 [53]; Matthews, B. 
D. et al. 2002 [68]; Komatsu, Y. et al. 2016 [64]; Jyotsna, V. P. et al. 2006 [62]; Hoem, 
D. et al. 2008 [59]; Mazzaglia, P. J. et al. 2007 [69]; Ayav, A. et al. 2005 [25]; Fu, W. 
et al. 2015 [50]; Fouda, M. A. . & Malabu, U. H. 2008 [49]; Ferrer-García, J. C. et al. 
2013 [48]; Hellman, P. et al. 2000 [57]; Grygiel, K. et al. 2012 [55]; Crippa, S. et al. 
2012 [39]; Bonato, F. T. et al. 2012 [32]; Bernard, V. et al. 2013 [28]; Bartsch, D. K. et 
al. 2000 [26]; Boukhman, M. P. et al. 1998 [33]; Creutzfeldt, W. et al. 1991 [38]; 
Eriksson, B. et al. 1990 [47] 
23 Gillams, A. et al. 2005 [52]; Van Den Akker, M. et al. 2012 [88]; Toaiari, 
M. et al. 2013 [85]; Placzkowski, A. et al. 2009 [77]; Mitrakou, A. et al. 
1993 [70]; Gopal, R. A. et al. 2010 [53]; Matthews, B. D. et al. 2002 
[68]; Komatsu, Y. et al. 2016 [64]; Jyotsna, V. P. et al. 2006 [62]; Hoem, 
D. et al. 2008 [59]; Mazzaglia, P. J. et al. 2007 [69]; Ayav, A. et al. 2005 
[25]; Fu, W. et al. 2015 [50]; Fouda, M. A. . & Malabu, U. H. 2008 [49]; 
Ferrer-García, J. C. et al. 2013 [48]; Hellman, P. et al. 2000 [57]; 
Grygiel, K. et al. 2012 [55]; Crippa, S. et al. 2012 [39]; Bonato, F. T. et 
al. 2012 [32]; Bernard, V. et al. 2013 [28]; Bartsch, D. K. et al. 2000 
[26]; Boukhman, M. P. et al. 1998 [33]; Creutzfeldt, W. et al. 1991 [38] 
Confusion 13 Besim, H. et al. 2002 [29]; Bonato, F. T. et al. 2012 [32]; Ferrer-García, J. C. et al. 
2013 [48]; Tavčar, I. et al. 2014 [84]; Boukhman, M. P. et al. 1998 [33]; Ding, Y. et al. 
2010 [41]; Komatsu, Y. et al. 2016 [64]; Larijani, B. et al. 2005 [65]; Nikfarjam, M. et 
al. 2008 [72]; Chung, J. C. et al. 2006 [36]; Dizon, A. M. et al. 1999 [42]; Doherty, G. 
et al. 1991 [43]; Eriksson, B. et al. 1990 [47] 
8 Tavčar, I. et al. 2014 [84]; Boukhman, M. P. et al. 1998 [33]; Ding, Y. et 
al. 2010 [41]; Komatsu, Y. et al. 2016 [64]; Larijani, B. et al. 2005 [65]; 
Nikfarjam, M. et al. 2008 [72]; Chung, J. C. et al. 2006 [36]; Dizon, A. 
M. et al. 1999 [42] 
Sweating 12 Grygiel, K. et al. 2012 [55]; Besim, H. et al. 2002 [29]; Boukhman, M. P. et al. 1998 
[33]; Bonato, F. T. et al. 2012 [32]; Jyotsna, V. P. et al. 2006 [62]; Nikfarjam, M. et al. 
2008 [72]; Tavčar, I. et al. 2014 [84]; Karakoc, D. et al. 2008 [63]; Dizon, A. M. et al. 
1999 [42]; Chung, J. C. et al. 2006 [36]; Larijani, B. et al. 2005 [65]; Eriksson, B. et al. 
1990 [47] 
5 Tavčar, I. et al. 2014 [84]; Karakoc, D. et al. 2008 [63]; Dizon, A. M. et 
al. 1999 [42]; Chung, J. C. et al. 2006 [36]; Larijani, B. et al. 2005 [65] 
Weight gain 12 Grygiel, K. et al. 2012 [55]; Fouda, M. A. . & Malabu, U. H. 2008 [49]; Karakoc, D. et 
al. 2008 [63]; Komatsu, Y. et al. 2016 [64]; Crippa, S. et al. 2012 [39]; Nikfarjam, M. 
et al. 2008 [72]; Dizon, A. M. et al. 1999 [42]; Bonato, F. T. et al. 2012 [32]; 
Boukhman, M. P. et al. 1998 [33]; Crona, J. et al. 2016 [40]; Jyotsna, V. P. et al. 2006 
[62]; Doherty, G. et al. 1991 [43] 
5 Bonato, F. T. et al. 2012 [32]; Boukhman, M. P. et al. 1998 [33]; Crona, 
J. et al. 2016 [40]; Jyotsna, V. P. et al. 2006 [62]; Doherty, G. et al. 
1991 [43] 
Syncope - 
temporary loss of 
consciousness 
10 Nikfarjam, M. et al. 2008 [72]; Bonato, F. T. et al. 2012 [32]; Grygiel, K. et al. 2012 
[55]; Chung, J. C. et al. 2006 [36]; Crona, J. et al. 2016 [40]; Dizon, A. M. et al. 1999 
[42]; Jyotsna, V. P. et al. 2006 [62]; Karakoc, D. et al. 2008 [63]; Tavčar, I. et al. 2014 
[84]; Besim, H. et al. 2002 [29] 
8 Grygiel, K. et al. 2012 [55]; Chung, J. C.. et al. 2006 [36]; Crona, J. et al. 
2016 [40]; Dizon, A. M. et al. 1999 [42]; Jyotsna, V. P. et al. 2006 [62]; 
Karakoc, D. et al. 2008 [63]; Tavčar, I. et al. 2014 [84]; Besim, H. et al. 
2002 [29] 
VIPOMA 
Diarrhea 7 Song, S. et al. 2009 [82]; Smith, S. L. et al. 1998 [81]; Peng, S. Y. et al. 2004 [75]; 
Nikou, C. et al. 2005 [73]; Matthews, B. D. et al. 2002 [68]; Ghaferi, A. A. et al. 2008 
[51]; Bartsch, D. K. et al. 2000 [26] 
7 Song, S. et al. 2009 [82]; Smith, S. L. et al. 1998 [81]; Peng, S. Y. et al. 
2004 [75]; Nikou, C. et al. 2005 [73]; Matthews, B. D. et al. 2002 [68]; 
Ghaferi, A. A. et al. 2008 [51]; Bartsch, D. K. et al. 2000 [26] 
Weight loss 5 Nikou, C. et al. 2005 [73]; Ghaferi, A. A. et al. 2008 [51]; Smith, S. L. et al. 1998 [81]; 
Peng, S. Y. et al. 2004 [75]; Matthews, B. D. et al. 2002 [68] 
3 Peng, S. Y. et al. 2004 [75]; Matthews, B. D. et al. 2002 [68]; Smith, S. 
L. et al. 1998 [81] 
Dehydration 3 Smith, S. L. et al. 1998 [81]; Nikou, C. et al. 2005 [73]; Peng, S. Y. et al. 2004 [75] 2 Nikou, C. et al. 2005 [73]; Peng, S. Y. et al. 2004 [75] 
Flushing 3 Ghaferi, A. A. et al. 2008 [51]; Smith, S. L. et al. 1998 [81]; Peng, S. Y. et al. 2004 [75] 0  
Abdominal pain 1 Smith, S. L. et al. 1998 [81] 0  
NON-FUNCTIONING 
This is the peer-reviewed but unedited manuscript version of the following article: Topping, M., Gray, D., Friend, E., Davies, A., & Ramage, J. (2017). A 
Systematic Review of Symptoms and Quality of Life Issues in Pancreatic Neuroendocrine Tumours, Neuroendocrinology (DOI: 10.1159/000475793).  The 
final, published version is available at https://doi.org/10.1159/000475793  
© 2017 Karger Publishers 
 
Abdominal pain 10 Bilchik, A. J. et al. 1997 [31]; Fu, W. et al. 2015 [50];  Butturini, G. et al. 2006 [34]; 
Eriguchi, N. et al. 1999 [46]; Gullo, L. et al. 2003 [56]; Liang, H. et al. 2004 [67]; Phan, 
G. Q. et al. 1998 [76]; White, T. J. et al. 1994 [92]; Tomassetti, P. et al. 2000 [86]; 
Hung, J. S. et al. 2007 [61] 
6 Eriguchi, N. et al. 1999 [46]; Gullo, L. et al. 2003 [56]; Liang, H. et al. 
2004 [67]; Phan, G. Q. et al. 1998 [76]; White, T. J. et al. 1994 [92]; 
Tomassetti, P. et al. 2000 [86] 
Jaundice 7 Nikou, G. C. et al. 2008 [74]; Liang, H. et al. 2004 [67]; Gullo, L. et al. 2003 [56]; 
Butturini, G. et al. 2006 [34]; Phan, G. Q. et al. 1998 [76]; White, T. J. et al. 1994 
[92]; Hung, J. S. et al. 2007 [61] 
0  
Anorexia 3 Gullo, L. et al. 2003 [56]; Phan, G. Q. et al. 1998 [76]; Butturini, G. et al. 2006 [34] 
  
0  
Vomiting 3 Butturini, G. et al. 2006 [34]; Liang, H. et al. 2004 [67]; Phan, G. Q. et al. 1998 [76] 0  
Back pain 3 Eriguchi, N. et al. 1999 [46]; Liang, H. et al. 2004 [67]; Hung, J. S. et al. 2007 [61] 0  
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Discussion 
This is the first systematic review of the literature relating to symptoms and QoL issues in all types of 
pNET for 20 years [97]. There are reviews investigating specific types of pNETs, such as insulinoma 
[98], glucagonoma [99], VIPoma [51];[81] and carcinoid pNETs [100], but not systematically 
reviewing the symptoms for all types. Much of the literature reviewed in this paper is a combination 
of clinical observation, and repetition of anecdotal historical observation. There are few papers 
systematically asking patients to record and score their symptoms, or asking health care workers to 
score patient symptoms.  
It is clear that many pNETs are now being picked up incidentally on routine scans, in patients without 
any symptoms. Those that can be removed surgically and cured will not have tumour-related 
symptoms, but many will have widespread disease and will develop symptoms later. The aim of this 
review has been to formally document what is known from the literature, with a view to developing 
more specific PROM/QoL outcome measures relating to the specific syndromes. We have used a 
systematic process to try to understand the most common PROMs in each of the pNET subtypes.  
pNETs are unique tumours setting them apart from most cancers, in that the symptoms of the 
hormone secreted may be the only symptoms present, without any generic cancer issues. It is 
evident from our findings that each pNET subtype presents differently, with different critical 
symptoms, thus it is likely that using generalised cancer questions in these patients may miss specific 
issues that are important. The main problem with assessing issues is that these tumours are rare and 
the subtypes of functioning tumours even more rare. It is therefore difficult to get a consensus of 
symptoms in so few patients.  With the onset of global reach of patient networks and online 
reporting worldwide, it is now easier to collect symptom data and a reasonable attempt can be 
made to get PROM data from the rarer syndromes. 
 As described, the mode of patient reporting is not often reported in the papers, so it is often not 
clear if patient views are being reported verbatim. There may well be a bias towards the clinician’s 
views of what is most important [101]. In addition the rarity of some of these syndromes prevents 
large datasets and by necessity involves recall of symptoms from small numbers of patients. The 
observed symptoms of the functional syndromes are slightly different to standard teaching hence 
this study provides evidence as to which symptoms should be measured in trials of novel therapies. 
The next stage from this data will be to do patient and healthcare professional interviews in large 
cohorts in many different languages across multiple countries to get their views on symptoms in 
pNET. The aim is to use the findings from this literature review, alongside the patient and healthcare 
workers interview data to create a list of QoL issues relevant and important to these patient groups, 
and from this create a QoL measure specific to pNET patients.  
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